Xeris Biopharma Holdings Inc
NASDAQ:XERS

Watchlist Manager
Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Watchlist
Price: 3.47 USD 1.46%
Market Cap: 517.3m USD
Have any thoughts about
Xeris Biopharma Holdings Inc?
Write Note

Xeris Biopharma Holdings Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xeris Biopharma Holdings Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Long-Term Debt
$216.2m
CAGR 3-Years
35%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Long-Term Debt
$31.3B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
9%
Bristol-Myers Squibb Co
NYSE:BMY
Long-Term Debt
$48.7B
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
21%
Pfizer Inc
NYSE:PFE
Long-Term Debt
$57.5B
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
6%
Merck & Co Inc
NYSE:MRK
Long-Term Debt
$35B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
Long-Term Debt
$29B
CAGR 3-Years
23%
CAGR 5-Years
16%
CAGR 10-Years
19%
No Stocks Found

Xeris Biopharma Holdings Inc
Glance View

Market Cap
517m USD
Industry
Pharmaceuticals

Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.

XERS Intrinsic Value
3.72 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Xeris Biopharma Holdings Inc's Long-Term Debt?
Long-Term Debt
216.2m USD

Based on the financial report for Sep 30, 2024, Xeris Biopharma Holdings Inc's Long-Term Debt amounts to 216.2m USD.

What is Xeris Biopharma Holdings Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
30%

Over the last year, the Long-Term Debt growth was 14%. The average annual Long-Term Debt growth rates for Xeris Biopharma Holdings Inc have been 35% over the past three years , 30% over the past five years .

Back to Top